Er Therapeutics Stock Probability of Future Stock Price Finishing Over 1.0E-4
| PNGM Stock | USD 0.0001 0.00 0.00% |
PNGM |
Er Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Er Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Er Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Er Therapeutics generated a negative expected return over the last 90 days | |
| Er Therapeutics has some characteristics of a very speculative penny stock | |
| Er Therapeutics currently holds 48.49 K in liabilities. Er Therapeutics has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Er Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (426.95 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Er Therapeutics currently holds about 650 in cash with (161.43 K) of positive cash flow from operations. | |
| Er Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Piedmont Lithium accelerates executive bonuses |
Er Therapeutics Technical Analysis
Er Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. PNGM Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Er Therapeutics. In general, you should focus on analyzing PNGM Stock price patterns and their correlations with different microeconomic environments and drivers.
Er Therapeutics Predictive Forecast Models
Er Therapeutics' time-series forecasting models is one of many Er Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Er Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Er Therapeutics
Checking the ongoing alerts about Er Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Er Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Er Therapeutics generated a negative expected return over the last 90 days | |
| Er Therapeutics has some characteristics of a very speculative penny stock | |
| Er Therapeutics currently holds 48.49 K in liabilities. Er Therapeutics has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Er Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (426.95 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Er Therapeutics currently holds about 650 in cash with (161.43 K) of positive cash flow from operations. | |
| Er Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Piedmont Lithium accelerates executive bonuses |
Check out Er Therapeutics Backtesting, Er Therapeutics Valuation, Er Therapeutics Correlation, Er Therapeutics Hype Analysis, Er Therapeutics Volatility, Er Therapeutics History as well as Er Therapeutics Performance. To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Diversified Metals & Mining space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Er Therapeutics. If investors know PNGM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Er Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (0.95) |
The market value of Er Therapeutics is measured differently than its book value, which is the value of PNGM that is recorded on the company's balance sheet. Investors also form their own opinion of Er Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Er Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Er Therapeutics' market value can be influenced by many factors that don't directly affect Er Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Er Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Er Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Er Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.